Healthcare
Nxera Pharma Co., Ltd.(SOLTF)
Live Price
Offline$6.19
+0.00% today
1Y Change
-11.64%
Window
Jun 23, 2025 โ Jun 17, 2026
- Market Cap
- $86.15B
- Revenue Growth
- +2.8%
- EPS Growth
- -158.8%
- Dividend Yield
- 0.0%
Coverage: 254 bars ยท Jun 23, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Nxera Pharma Co., Ltd. (SOLTF) is a Healthcare stock with a market cap of $86.15B and listed on OTC. The stock last traded around $6.18 and down 11.6% across the available one-year price window (Jun 23, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +2.8%, EPS growth of -158.8%, a dividend yield of 0.0%. What stands out right now is revenue +2.8%, EPS -158.8%, free cash flow +66.3% with operating margin -6.6% and ROIC -1.8%. Valuation is more restrained than many high-expectation growth names at price/sales 2.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SOLTF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+2.8% vs +7.6% peer median
Operating Margin
Below sector median
-6.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 1, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +2.8% and EPS is at -158.8%, with operating margin around -6.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.5% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 1, 2026 | โ | +0.0% | +0.0% | +4.6% |
2026 Feb 13, 2026 | -215.7% | +0.0% | +0.0% | +0.0% |
2025 Aug 8, 2025 | -247.1% | +4.5% | -4.5% | +14.6% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SOLTF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SOLTF Max Drawdown
-31.81%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SOLTF and SPY.
Company Overview
Nxera Pharma Co., Ltd.
Other OTC
Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company's development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders. It is also involved in the development of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; and other discovery and preclinical stage drugs. Nxera Pharma Co., Ltd. has a strategic collaboration with AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Tokyo, Japan.
- Leadership
- Christopher Cargill
- IPO Date
- Sep 4, 2013
- Employees
- 387
- Street Address
- PMO Hanzomon
- Mailing
- Tokyo, 102-0083
- Region
- Tokyo, JP
- Reporting Currency
- USD
- Investor Line
- 81 3 5210 3290
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 61.2
- Price/Sales
- 2.5
- Price/Book
- 1.4
Growth
- Revenue
- +2.8%
- EPS
- -158.8%
- Free Cash Flow
- +66.3%
Profitability
- Gross Margin
- 77.5%
- Operating Margin
- -6.6%
- Net Margin
- -29.1%
- ROE
- -15.6%
- ROIC
- -1.8%
Balance Sheet
- Debt/Equity
- 0.88
- Current Ratio
- 2.61
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.